WIN BOLD MISSION: Significantly improve survival of cancer patients across the world through international collaboration.

STRATEGY: Perform proof-of-concept cancer clinical trials designed to explore novel strategies and tools to increase efficacy of Precision Oncology and improve early diagnosis

WIN Publications

- **WINther trial results**

- **Simplified interventional mapping system (SIMS)**


- **Digital Display Precision Predictor (DDPP)**

  Lazar, V., et al., Transcriptomics in tumor and normal lung tissues identify patients with early stage NSCLC with high risk of post-surgery recurrence who may benefit from adjuvant therapies. *JCO Precision Oncology* no. 6 (2022) e2200072. Published online


WIN New Leadership

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Mendelsohn</td>
<td>Chair, WIN 2010 - 2018</td>
<td>Past President MD Anderson Cancer Center, Houston, USA</td>
</tr>
<tr>
<td>Thomas Tursz</td>
<td>Vice-Chair, WIN 2010 - 2012, 2016 - 2018</td>
<td>Past General Director Gustave Roussy, Villejuif, France</td>
</tr>
<tr>
<td>Alexander Eggermont</td>
<td>Vice-Chair, WIN 2012 - 2016</td>
<td>Past General Director Gustave Roussy, Villejuif, France</td>
</tr>
<tr>
<td>Josep Tabernero</td>
<td>Vice-Chair, WIN 2018 - 2023</td>
<td>Head Vall d’Hebron Institute of Oncology, Barcelona, Spain</td>
</tr>
<tr>
<td>Richard L. Schilsky</td>
<td>Chair, WIN 2018 - 2023</td>
<td>Past President, former Executive VP and Chief Medical Officer, ASCO, USA</td>
</tr>
<tr>
<td>Wafik El-Deiry</td>
<td>Chair, WIN 2024 -</td>
<td>Director, Legorreta Cancer Center, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University, Providence, USA</td>
</tr>
</tbody>
</table>

WIN History

WIN was founded in France as a non-profit by Dr. John Mendelsohn, Past President MD Anderson Cancer Center, Houston, Chairman of WIN until his death and Prof. Thomas Tursz, General Director Gustave Roussy, France.

WIN was formed on the premise that Consortium members can accomplish together what no single institution or group of patients can do alone.

WIN was founded in France as a non-profit by Dr. John Mendelsohn, Past President MD Anderson Cancer Center, Houston, Chairman of WIN until his death and Prof. Thomas Tursz, General Director Gustave Roussy, France.

WIN BOLD MISSION: Significantly improve survival of cancer patients across the world through international collaboration.

STRATEGY: Perform proof-of-concept cancer clinical trials designed to explore novel strategies and tools to increase efficacy of Precision Oncology and improve early diagnosis

---

**Digital Display Precision Predictor (DDPP)**


Lazar, V., et al., Transcriptomics in tumor and normal lung tissues identify patients with early stage NSCLC with high risk of post-surgery recurrence who may benefit from adjuvant therapies. *JCO Precision Oncology* no. 6 (2022) e2200072. Published online


### WIN 27 Members

#### WIN Consortium Members

<table>
<thead>
<tr>
<th>Academic Institutions in Americas</th>
<th>Industries</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="#" alt="Brown" /></td>
<td><img src="#" alt="Illumina" /></td>
</tr>
<tr>
<td><img src="#" alt="Averya" /></td>
<td><img src="#" alt="Avista" /></td>
</tr>
<tr>
<td><img src="#" alt="Cancer Institute" /></td>
<td><img src="#" alt="Healthcare" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Academic Institutions in Asia</th>
<th>Non-Profit Organizations</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="#" alt="Universities in Asia" /></td>
<td><img src="#" alt="ECCO" /></td>
</tr>
<tr>
<td><img src="#" alt="Cancer Centers in Asia" /></td>
<td><img src="#" alt="Target Cancer Foundation" /></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Academic Institutions in Europe</th>
<th>World-class academic medical centers (23), industries (1), research and patient advocate organizations (3).</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="#" alt="Universities in Europe" /></td>
<td>27 members in 18 countries and 5 continents Access to &gt; 5,000,000 patients <a href="http://www.winconsortium.org">www.winconsortium.org</a> <a href="http://www.winssymposium.org">www.winssymposium.org</a></td>
</tr>
</tbody>
</table>

### WIN Value Proposition

- **Access to:**
  - Global thought leaders in Precision Oncology
  - Platform of leading cancer centers across the world

- **Expertise in genomics and transcriptomics**

- **Experience and success with:**
  - Complex biomarker-directed clinical trials (WINHER trial)
  - Obtaining high quality tissues and bloods for comprehensive genomics and transcriptomics
  - Managing international multi-site trials
  - International Molecular Tumor Board

- **Ability to partner with companies and philanthropic organizations or individuals to perform Precision Oncology studies to:**
  - Better identify treatment options for patients including optimal dosing of novel combination therapies
  - Understand mechanisms of resistance to cancer therapy
  - Improve patients’ treatment follow-up and early diagnosis non-invasively
  - Accelerate drug development through better patient selection

### A Vision for WIN’s Future

- **Expand the WIN membership with additional:**
  - World-class cancer centers in US and across the globe
  - Diagnostics, AI, pharma companies, patient-advocacy organizations, non-profits

- **Leveraging WIN’s platform for global academic members to:**
  - Partner with companies for compelling Precision Oncology and Early Diagnosis studies across the globe
  - Build upon transcriptomics’ experience acquired in international clinical trials like WINHER and others that have so much potential
  - Accelerate trial results delivery and simplify management of multi-site international trials

- **Leverage WIN IP (algorithm for patient’s treatment matching and patient stratification)**

- **New initiatives such as international Molecular Tumor Board**

- **Catalyze Think Tanks to pursue the most exciting directions, involve WIN’s exceptional SAB; Innovation and Collaboration globally to ensure continued success**

- **Strengthen relationships with professional societies (ACS, ASCO, AACI, AACR, etc.)**

---

WIN’s 13th symposium by co-chairs Prof. W El-Deiry and Dr. R Kurzrock in a serie of remarkable ASCO and ESO endorsed symposia.

1-2 March 2024 in Rosewood Hotel, Abu Dhabi, UAE

**Nobel Laureate Jim Allison** (MDACC)  
**Padmanee Sharma** (MDACC)  
**Vivek Subbiah** (Sarah Cannon Research Institute)  
**Sendurai Mani** (Brown University)
Organizations we have collaborated with

- Representation at international general assembly (right to vote on all decisions)
- Access to governance positions (2-year mandates)
- Ability to participate in WIN-managed studies
- Ability to propose studies to be performed in WIN member institutions, but no obligation
- Each project is subject to contract negotiated in good faith. Usual IP rules apply
- Each project needs a separate funding mechanism. All participants in studies required to participate in the effort
- Visibility on website, symposia

**Annual Membership Dues**
Academics: From 5,000 to 50,000 € depending on research budget
Industries: Pharma 250,000 €; Technology partners 100,000 €